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Abstract
Aims—The objective was to describe the prevalence of diabetes-related foot complications in a
managed care population and to identify the demographic and biological risk factors.
Methods—We assessed the period prevalence of foot complications on 6,992 patients using
ICD-9 diagnosis codes from health plan administrative data. Demographic and biological
variables were ascertained from surveys and medical record reviews. We defined four mutually
exclusive groups: any Charcot foot, DFU with debridement, amputation ± DFU and debridement,
and no foot conditions.
Results—Overall, 55 (0.8%) patients had Charcot foot, 205 (2.9%) had DFU with debridement,
and 101 (1.4%) had a lower-extremity amputation. There were 6,631 patients with no prevalent
foot conditions. Racial/ethnic minorities were less likely to have Charcot foot (OR=0.21; 95%CI:
0.10, 0.46) or DFU (OR=0.61; 95% CI: 0.44, 0.84) compared to non-Hispanic Whites, but there
were no racial/ethnic differences in amputation. Histories of micro- or macrovascular disease were
associated with a two- to four-fold increase in the odds of foot complications.
Conclusion—In managed care patients with uniform access to health care, we found a relatively
high prevalence of foot complications, but attenuation of the racial/ethnic differences of rates
reported in the literature.
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Introduction
Diabetes can lead to a number of debilitating foot complications, including Charcot
neuroosteoarthropathy, diabetic foot ulceration (DFU), and lower extremity amputation.
Charcot neuroosteoarthropathy is a destructive joint disorder initiated by trauma to an
insensate limb that leads to inflammation and collapse of the normal foot architecture (1).
The prevalence of Charcot neuroosteoarthropathy among patients with diabetes has been
reported to be between 0.1% and 0.9% (2-4). It has been estimated that 63% of patients with
Charcot neuroosteoarthropathy will develop a foot ulcer (5), and the co-occurrence of
Charcot and DFU confers a 12-fold higher risk of amputation (6). Peripheral
polyneuropathy, foot deformities, and peripheral vascular disease contribute to DFU and
amputation. It is estimated that people with diabetes have a 25% lifetime risk of developing
a foot ulcer (7), and 84% of lower extremity amputations have been attributed to non-
healing DFUs (8).
In the United States, as many as 15% of people with diabetes will have lower extremity
amputations during their lifetime (9), and substantially higher rates are associated high-risk
foot conditions like Charcot neuroosteoarthropathy and DFU (10). While the causal
pathways leading to Charcot and DFU, or eventually, lower-extremity amputation, may
differ, they are all identified by comprehensive foot examination including inspection of the
dermatologic and musculosketal systems, sensory examination, and pulse evaluation, and
with appropriate treatment, often are preventable (11). The American Diabetes Association
(ADA) has concluded that preventive care teams, defined as multidisciplinary teams that
utilize risk assessment tools, patient education, and therapeutic footwear, can decrease the
risk of DFU and amputation by 50-85% (12). Managed care organizations, which provide
access to care and prevention, should be well positioned to screen and prevent foot
complications. Studies have not yet reported on the prevalence and risk factors of diabetic
foot complications in managed care organizations other than in the VA (6,10,13-15). Our
objective was to describe the prevalence of diabetes-related foot complications in a managed
care population and to identify the demographic and biological risk factors associated with
each of the three major diabetes-related foot complications.
Materials and Methods
Study population
Translating Research Into Action for Diabetes has been described elsewhere (16). Briefly,
TRIAD studied a random sample of adults with diabetes enrolled in 10 managed care health
plans in eight states (California, Hawaii, Indiana, Michigan, New York, New Jersey,
Pennsylvania, and Texas) that served ~180,000 patients with diabetes. Patients were eligible
to participate if they were at least 18 years old, lived in the community, were not pregnant,
had diabetes for at least 1 year, spoke either English or Spanish, were continuously enrolled
in the health plan for at least 18 months, used at least one service during that time, and could
give informed consent. Institutional review boards at each participating site approved the
study.
In 2000-2001, we administered a survey by computer-assisted telephone interview or in
writing by mail. In addition, centrally trained reviewers used standardized collection
methods to abstract medical records. Health plan administrative data were collected for 1999
through 2003. The analytic sample for this study included participants who had survey and
medical record data at baseline and were members of a site participating in the 2010-2013
TRIAD Legacy Study (N=6,992).
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Outcomes
We used 1999-2003 health plan administrative data to determine the period prevalence of
the three specific foot conditions: Charcot neuroosteoarthropathy, diabetic foot ulcer (DFU),
and amputation. Charcot neuroosteoarthropathy, referred to as Charcot foot, was defined as
the presence of the International Classification of Diseases, 9th Revision (ICD9), diagnosis
code 713.5 in any inpatient or outpatient records (14). DFUs were defined using either ICD9
codes 707.1× or 707.9 in any inpatient or outpatient records (15). To try to narrow the scope
to persons with prevalent DFUs, we also required that the participant have at least one CPT
code for debridement (11040, 11041, 11042, 11043, or 11044). Amputation was defined as
the presence of at least one ICD9 procedure code for amputation (84.11, 84.12, 84.13-84.16,
or 84.17-84.19), ICD9 status code for amputation (v49.7), or CPT code for amputation
(27590-8, 27880-9, 28800, 28805, 28810, 28820, or 28825) in any inpatient or outpatient
records (10).
Covariates
Variables that we investigated as possible predictors of each of the three foot conditions
included demographic variables (age, sex, race/ethnicity, education, income, and smoking),
diabetes-specific variables (type of diabetes, duration of diabetes, insulin use, and
hemoglobin A1c), and biological variables (body mass index, systolic and diastolic blood
pressure, low density lipoprotein cholesterol, triglycerides, history of microvascular
complications, history of macrovascular complications, and Charlson comorbidity index).
Smoking was considered present if the participant had ever smoked as defined by a positive
response to either self-report of current smoking some days or every day, or a history of
smoking in the past three years from medical record review. Type 1 diabetes was defined by
insulin use (without the use or oral antidiabetic agents) and age at diagnosis of diabetes < 30
years; all others were defined as having type 2 diabetes. History of microvascular disease
was defined as a history of retinopathy, nephropathy, or neuropathy from medical record
review. History of macrovascular disease was defined as a history of stroke, myocardial
infarction, or peripheral vascular disease from medical record review. The number of
comorbidities was defined using the Charlson index, a weighted measure of comorbid
conditions associated with mortality (17). Other variables included in Table 1, including
health-related quality of life (EQ5D), mobility, physical activity, and foot care behaviors,
were used to describe the population with foot conditions and were not included as possible
predictors of foot complications because they may have been influenced by the presence of
Charcot foot, DFU, and amputation. Limits were set on outliers for certain variables as such:
time others spend on your foot care (60 min per day), time you spent on foot care (7 hrs per
week), and time you spent exercising (120 min per day).
Statistical Analysis
We defined each person as having none or one or more foot conditions and examined the
occurrence of prevalent conditions using a Venn diagram (Figure 1). We then used a
hierarchy to place each person with a foot condition into one of three mutually exclusive
groups: any Charcot foot, DFU and debridement only, or amputation with or without DFU
and debridement. We described the percent distribution of categorical variables and the
mean ± standard deviation of continuous variables for people in each of the three groups.
Chi-square and t-tests were conducted to compare each group separately to the reference
group of people with no foot conditions.
Three separate mulitvariate logistic regression models were constructed to predict Charcot
foot, DFU, or amputation. Each model used the population with no foot conditions as the
reference group. The models were adjusted for clustering at the provider group and health
plan level. We constructed the multivariate models first by including sex and race/ethnicity
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in each model and then including all variables that were statistically significant at a p-value
of < 0.05 in bivariate analyses. Insulin use and duration of diabetes were highly correlated
(p<0.0001) so we chose to only include duration of diabetes in the models.
All analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC).
Results
At baseline, the average age of TRIAD participants was 61 (±13) years and mean duration
of diabetes was 12 (±10) years. Between 1999-2003, 55 (0.8%) patients had a diagnosis of
Charcot foot, 205 (2.9%) had a diagnosis of at least one DFU with incident debridement,
and 101 (1.4%) had a lower extremity amputation procedure or a status code for a prevalent
amputation. There were 6,631 (94.8%) patients with no foot conditions.
In the bivariate models (Table 1), patients with Charcot foot were more likely to be men,
less likely to be a racial/ethnic minority, and more likely to have a longer duration of
diabetes, to use insulin, and to have microvascular disease. They also were more likely to
have a higher BMI, a history of macrovascular disease, and a higher Charlson comorbidity
index compared to patients with no foot conditions. Patients with DFU were more likely to
be older and less likely to be a racial/ethnic minority. They were more likely to have a
longer duration of diabetes and use insulin, a higher hemoglobin A1c level, a history of
microvascular and macrovascular disease, and a higher Charlson comorbidity index
compared to patients with no foot conditions. Patients with a lower extremity amputation
were more likely to be men, have a lower income, have a longer duration of diabetes and use
insulin, have a higher hemoglobin A1c level, have a history of microvascular and
macrovascular disease, and have a higher Charlson comorbidity index compared to patients
with no foot conditions.
Patients with any of the three foot conditions reported poorer quality of life and more
problems walking than patients with no foot conditions. Patients with a foot condition were
significantly more likely to check their feet daily and spend more time on daily foot care
(Table 1).
In the multivariate models (Table 2), racial/ethnic minorities were less likely to have
Charcot foot (OR=0.21; 95% CI:0.10, 0.46) than non-Hispanic Whites. Longer duration of
diabetes and higher body mass index were associated with Charcot foot. Patients with a
history of microvascular disease were almost four times as likely to have Charcot foot as
patients without microvascular disease (OR=3.62; 95%CI: 1.92, 6.82) and patients with a
history of macrovascular disease were almost twice as likely to have Charcot foot as patients
without macrovascular disease (OR=1.87; 95%CI: 1.07, 3.27). hemoglobin A1c was not
associated with Charcot foot.
Compared to non-Hispanic Whites, racial/ethnic minorities were less likely to have DFU
(OR=0.61; 95% CI: 0.44, 0.84). Longer duration of diabetes and higher hemoglobin A1c
levels were associated with DFU. Patients with a history of microvascular (OR=2.32;
95%CI: 1.65, 3.27) or macrovascular disease (OR=2.23; 95% CI: 1.59, 3.12) were over
twice as likely to have DFU compared to those without a history of microvascular or
macrovascular disease (Table 2).
Compared to women, men were more likely to have a lower-extremity amputation
(OR=2.40; 95% CI: 1.41, 4.07). Longer duration of diabetes and higher hemoglobin A1c
levels were associated with amputation. Patients with a history of microvascular (OR=3.09;
95%CI: 1.79, 5.34) or macrovascular disease (OR=3.36; 95% CI: 1.96, 5.75) were over
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three times as likely to have an amputation compared to those without a history of
microvascular or macrovascular disease (Table 2).
Discussion
In our study of managed care patients, we found a relatively high prevalence of foot
complications, particularly given uniform access to health care for all patients. Racial/ethnic
minorities were less likely to have Charcot foot and DFU, and there were no racial/ethnic or
income differences in the prevalence of lower-extremity amputation. Few studies have
evaluated the racial/ethnic differences in the prevalence of Charcot foot (1). In one small
study of foot pathology, Lavery et al. reported that Charcot foot was more common among
non-Hispanic Whites (4). Likewise, Stuck et al. (14) found that African Americans were less
likely to have Charcot foot. In keeping with these reports, we also found racial/ethnic
minorities to be less likely to have Charcot foot. Previous literature has suggested that
patients with lower socioeconomic status and minorities with diabetes, particularly African
Americans, are more likely to have DFU and lower extremity amputation and to have a
more severe (i.e., more proximal) amputation than patients with higher socioeconomic status
and non-Hispanic Whites (18- 21). However, our work confirms a previous study (22) that
found no difference in amputation rates among blacks, whites, and Latinos with access to
good quality healthcare.
A major strength of our study is the evaluation of Charcot foot among a managed care
population with diabetes. Charcot foot is an infrequent complication that may be
underdiagnosed, even among populations with diabetes. Previous reports of Charcot foot
indicate a prevalence of 0.1-0.9% among patients with diabetes (2- 4), which is in keeping
with our findings. Unlike previous investigations that have found no association between sex
and Charcot foot, we found that men were marginally more likely to have Charcot foot than
women. Additional research is needed to understand the reason for sociodemographic
differences in the prevalence of Charcot foot. It has been hypothesized that the presence of
peripheral neuropathy, combined with the biomechanical loading of obesity, confers greater
risk of Charcot foot (14). We found a significant independent association between BMI and
Charcot foot as well as between microvascular disease and Charcot foot. Although we did
not have enough statistical power to evaluate the interaction between BMI and peripheral
neuropathy in our study population, our findings suggest the importance of body size and
loss of protective pain sensation in the pathology of Charcot foot. We were able to
investigate the BMIs among the two racial/ethnic groups and found that non-Hispanic
whites (31.5 kg/m2) had a similar BMI to racial/ethnic minorities (31.4 kg/m2) (p=0.4290),
indicating that the difference in risk for Charcot foot by race/ethnicity was likely not due to
differences in obesity.
For all three foot conditions, the strongest associations were observed with history of
microvascular and macrovascular disease. History of microvascular disease was associated
with a two- to four-fold increase in the odds of foot complication, and history of
macrovascular disease was associated with a two- to three-fold increase in the odds of foot
complications. In sensitivity analyses (results not shown), we evaluated each component of
the microvascular summary variable (retinopathy, nephropathy, and neuropathy) and the
macrovascular summary variable (stroke, MI, and PVD) separately in our multivariate
models for DFU and amputation. Retinopathy and nephropathy were moderately associated
with the odds of DFU (approximately 1.8-fold increase), and neuropathy was strongly
associated (approximately 2.6-fold increase) with DFU. Nephropathy and neuropathy were
both associated with an approximately 2.3-fold increase in the odds of lower-extremity
amputation, but retinopathy was not associated with amputation. PVD was the strongest and
only statistically significant contributor to the association between macrovascular disease
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and DFU and amputation, which is not surprising since impaired circulation resulting from
PVD may decrease wound healing. This is also consistent with prior reports in this area
(23-24). Likewise, loss of protective sensation is associated with Charcot foot, DFU, and
amputation.
In addition to microvascular and macrovascular disease, all three foot conditions were
associated with longer duration of diabetes. There were also important differences between
Charcot foot, DFU, and amputation with respect to other risk factors. BMI was associated
with Charcot foot but not with DFU or amputation. Our findings are consistent with those
previously reported for obesity with Charcot foot and amputation (14; 25). Our findings
differ from Sohn and colleagues for obesity and foot ulcer risk. Their study reported a j-
shaped relationship of increased risk of foot ulcer for those BMI’s <25 or greater than 40
(26). Hemoglobin A1c was associated with DFU and amputation, but not Charcot foot. We
hypothesize that it is the combination of peripheral neuropathy from long-standing diabetes,
whether the diabetes is well-controlled or not, and the biomechanical loading of obesity
which plays a substantial role in the development of Charcot foot. This differs from the
development of amputation which is more impacted by the degree of micro- and
macrovascular complications that develop at differing rates in patients with varying levels of
control of their diabetes.
This study has some limitations. Identification of foot conditions relied on data recorded for
administrative purposes. These data may not accurately represent a patient’s clinical status.
However, previous studies have reported that compared to medical records, ICD-9 codes
have 93% sensitivity and 91% specificity to identify DFU, and that Charcot arthropathy
identified by ICD-9 codes can be confirmed by medical records 92% of the time (6, 15).
Administrative data do not allow for identification of the foot affected so we do not know if
the conditions were unilateral or bilateral. Additionallydue to the relatively low prevalence
of Charcot foot and subsequently limited statistical power, we combined all racial/ethnic
minority groups into a single category and compared them to non-Hispanic Whites. As such,
heterogeneity within racial/ethnic minorities may have been masked and it is possible that
African Americans, Hispanics, and Asians have important differences in the prevalence and
correlates of diabetes-related foot complications. We did not observe an association between
smoking and foot complications. However, due to survey measurement, the dichotomization
of smoking may have resulted in misclassification and biased the results of our bivariate
analysis of smoking and foot complications. BMI was measured by self-report, which also
may have resulted in misclassification.
Early detection of feet at risk and appropriate management are the most important factors in
preventing diabetes-related foot complications. In our study of managed care patients with
uniform access to health care, we found a relatively high prevalence of foot complications,
but attenuation of the racial/ethnic differences of rates reported in the literature.
Multidisciplinary preventive health care teams may reduce high rates of amputation in
persons with diabetes.
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Figure 1.
Coinciding counts of prevalent foot conditions for patients with survey and chart review
data, Translating Research Into Action for Diabetes N=6,992.
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